Company Name Edison Pharmaceuticals
Mailing Address 350 N. Bernardo Ave. Mountain View, CA 94043
Company Description Edison’s business is the development of drugs to treat diseases that impair energy metabolism. Energy impairment diseases can be classified on the basis of whether they are inherited or acquired, and furthermore on the location of the defect. Edison is initially focusing on inherited diseases of the mitochondria- nature’s biological energy substation.
Proceeds Purposes Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich’s ataxia. Additional clinical development initiatives are underway and will be announced in Q1 2013.